Homologous telomerase gene sequences
This group of patents – three of which are owned by Geron and University of Colorado (individually or jointly), one of which is co-owned by Geron and Albert Einstein College of Medicine, and one of which is owned by Research & Development Institute in Montana – concern nucleic acid sequences and gene products of telomerase from other species. By no means does this group exhaust the species from which telomerase gene has been cloned; telomerase from other species can be found in the scientific literature.
The species represented in this group are:
- Candida albicans (US 6,541,202);
- Euplotes (US 6,093,809 and US 6,166,178);
- Schizosaccharomyces pombe (US 6,309,867);
- Mus musculus (US 6,767,719).
|
Patent Data |
Title and relevant claims |
Family Data |
|
Assignee: University Technology Corp. Geron Corp. Earliest priority: 01 Oct 1996 Filed: 06 May 1997 Granted: 25 Jul 2000 Expiry date: 01 Oct 2016 |
Telomerase Claim 1: An isolated polynucleotide consisting of the nucleic acid sequence shown in SEQ. ID. No. 1. No other claims. |
No functionally related patents or applications – published in English |
|
US 6,166,178 Assignee: University Technology Corp. Geron Corp. Earliest priority: 01 Oct 1996 Filed: 19 Nov 1997 Granted: 26 Dec 2000 Expiry date: 01 Oct 2016 |
Telomerase catalytic subunit Claim 1: An isolated polypeptide consisting of the amino acid sequence shown in SEQ ID. NO. 110. No other claims. |
No functionally related patents or applications – published in English |
|
US 6,309,867 Assignee: University Technology Corp. Earliest priority: 01 Oct 1996 Filed: 29 Oct 1999 Granted: 30 Oct 2001 Expiry date: 01 Oct 2016 |
Telomerase Claim 1: An isolated polypeptide consisting of the amino acid sequence shown in SEQ. ID. NO. 69. No other claims |
No functionally related patents or applications – published in English |
|
US 6,541,202 Assignee: Research & Development Institute Filed: 13 Oct 1999 Granted: 01 Apr 2003 Expiry date: 13 Oct 2019 |
Telomerase reverse transcriptase (TERT) genes from Candida albicans Claim 1: An isolated nucleic acid molecule having at least 80% identity to a polynucleotide molecule that encodes the amino acid sequence of SEQ ID NO:2 or SEQ ID NO: 4, wherein said nucleic acid molecule encodes an amino acid sequence having telomerase reverse transcriptase activity. |
AU 2000/80023 A5 US 2003/134275 A1 W0 01/27287 A1 |
|
US 6,767,719 Assignee: Geron Corp. Albert Einstein College of Medicine Earliest priority: 26 Nov 1997 Filed: 16 Mar 1998 Granted: 27 Jul 2004 Expiry date: 26 Nov 2017 * |
Mouse telomerase reverse transcriptase Claim 1: An isolated, purified or recombinant polynucleotide encoding a telomerase reverse transcriptase protein, wherein said protein: (i) has at least 90% sequence identity to SEQ. ID NO:2; (ii) has telomerase catalytic activity when associated with telomerase RNA component; and (iii) contains at least one of the following amino acid motifs; Motif T: W-X12 -FFY-X1 -TE-X11 -R-X3 -W; Motif 1: LR-X1 -IPK; Motif 2: R-X1 -I-X15 -K; Motif A: P-X3 -F-X3 -D-X4 -YD; Motif B: Y-X4 -G-X2 -QG-X3 -S; Motif C: DD-X1 -L; or Motif D: A-X2 -F-X18 -K; wherein Xn is a sequence of unspecified amino acids of length "n". |
See Appendix 1 for complete list. No applications or patents filed outside of U.S. with claims to mouse TERT |
* - A terminal disclaimer was filed for this patent. Without obtaining the full prosecution history of this patent to reveal which patent it was disclaimed in favor of, certainty of the expiry date is not possible.
[1] An interference is a procedure conducted by the United States Patent and Trademark Office when multiple applications have identical claims. The purpose of an interference is to determine who was the first-in-time inventor and so deserves the patent.
[2] For a review of hybridization, see www.roche-applied-science.com/PROD_INF/MANUALS/InSitu/pdf/ISH_33-37.pdf.
[3] Geron has many pending patent applications on telomerase, some of which may contain claims directed to disclosure that isn’t claimed in this patent.
There are no comments.